AQR Capital Management LLC Invests $36,000 in Ikena Oncology, Inc. (NASDAQ:IKNA)

AQR Capital Management LLC purchased a new stake in Ikena Oncology, Inc. (NASDAQ:IKNA) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,861 shares of the company’s stock, valued at approximately $36,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC acquired a new position in Ikena Oncology in the second quarter valued at approximately $30,000. BBR Partners LLC acquired a new position in Ikena Oncology during the 2nd quarter valued at approximately $33,000. Acadian Asset Management LLC boosted its position in Ikena Oncology by 15.2% during the 2nd quarter. Acadian Asset Management LLC now owns 325,713 shares of the company’s stock valued at $536,000 after purchasing an additional 42,931 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Ikena Oncology during the 2nd quarter worth $75,000. Finally, JBF Capital Inc. bought a new stake in Ikena Oncology in the second quarter valued at $120,000. 75.00% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Ikena Oncology in a research report on Monday, August 12th.

Ikena Oncology Price Performance

Shares of NASDAQ:IKNA opened at $1.71 on Friday. The stock has a market cap of $82.52 million, a price-to-earnings ratio of -1.08 and a beta of 0.49. Ikena Oncology, Inc. has a 12 month low of $1.02 and a 12 month high of $4.63. The stock’s 50 day moving average price is $1.70 and its 200 day moving average price is $1.59.

Ikena Oncology (NASDAQ:IKNA) last issued its earnings results on Thursday, August 8th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. On average, sell-side analysts expect that Ikena Oncology, Inc. will post -1.03 EPS for the current year.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.